Risk factors and recurrence characteristics of neuromyelitis optica spectrum disease
-
摘要:
目的 通过对视神经脊髓炎谱系疾病(NMOSD)的病例研究,探讨NMOSD的危险因素和复发特点。 方法 纳入2016年1月—2017年8月在蚌埠医学院第一附属医院神经内科和重庆陆军特色医学中心神经内科确诊的204例NMOSD患者,男性54例,女性150例,平均年龄37.5岁。对照组818例, 与NMOSD组年龄相匹配。收集患者一般临床资料和血清AQP4-IgG水平,并对相关因素进行分析。 结果 多因素分析发现女性、劳累史、既往合并其他自身免疫性疾病的患者发生风险增加2倍以上(OR=2.473,95% CI: 1.714~3.486;OR=2.319,95% CI: 1.573~3.349;OR=2.210,95% CI: 1.001~4.740),低经济收入水平者、有上呼吸道感染史、妇科手术/产科手术史、饮酒史和创伤手术史的研究对象发生NMOSD风险增加1.5倍以上(OR=1.502,95% CI: 1.020~2.121;OR=1.651,95% CI: 1.121~2.382;OR=1.712,95% CI: 1.060~3.375;OR=1.830,95% CI: 1.011~3.184;OR=1.928,95% CI: 1.032~3.516)。 结论 经济收入水平、劳累史、上呼吸道感染史、妇科手术/产科手术、创伤手术史、饮酒史和既往合并其他自身免疫性疾病在一定程度上可能是NMOSD发生的危险因素,NMOSD患者复发可能会导致更严重的临床症状、影像学表现及更差的预后。 Abstract:Objective To investigate the risk factors and recurrence characteristics of neuromyelitis optica spectrum disease (NMOSD) through a case study. Methods Total 204 NMOSD patients diagnosed in the Department of Neurology of the First Affiliated Hospital of Bengbu Medical College and the Department of Neurology of Chongqing Army Characteristic Medical Center were included from January 2016 to August 2017. There were 54 males and 150 females, with an average age of 37.5 years. There were 818 cases in the control group, which matched the age of the NMOSD group. Patients' general clinical data and serum AQP4-IgG levels were collected, and related factors were analysed. Results Multivariate analysis found that women with a history of exertion and patients with previous autoimmune diseases increased the risk more than 2 times (OR=2.473, 95% CI: 1.714-3.486; OR=2.319, 95% CI: 1.573-3.349; OR=2.210, 95% CI: 1.001-4.740). For people with low income level, history of upper respiratory tract infection, history of gynaecological surgery/obstetric surgery, alcohol consumption, the risk of patients with history and trauma surgery increased by more than 1.5 times (OR=1.502, 95% CI: 1.020-2.121; OR=1.651, 95% CI: 1.121-2.382; OR=1.712, 95% CI: 1.060-3.375; OR=1.830, 95% CI: 1.011-3.184; OR=1.928, 95% CI: 1.032-3.516). Conclusion Economic income level, history of fatigue, history of upper respiratory tract infection, history of gynaecological surgery/obstetric surgery, history of trauma surgery, history of drinking and other autoimmune diseases may be risk factors for NMOSD to a certain extent. Recurrence of NMOSD patients may lead to more severe clinical symptoms, imaging findings and worse prognosis. -
Key words:
- Neuromyelitis optica spectrum disease /
- Risk factors /
- Relapse
-
表 1 NMOSD患者危险因素的单因素分析[例(%)]
组别 例数 性别 年龄(岁) 经济收入水平 劳累史 男性 女性 ≥40 <40 中高经济水平 低 正常对照组 818 359(43.9) 459(56.1) 342(41.8) 476(58.2) 667(81.5) 151(18.5) 104(12.7) NMOSD组 204 54(26.5) 150(73.5) 89(43.6) 115(56.4) 153(75.0) 51(25.0) 37(18.1) χ2值 20.569 0.221 4.404 4.038 P值 <0.001 0.638 0.036 0.044 组别 例数 上呼吸道感染史 妇科手术/产科手术 创伤手术史 饮酒史 吸烟史 既往合并其他自身免疫性疾病 正常对照组 818 138(16.9) 22(2.7) 35(4.3) 42(5.1) 43(5.3) 19(2.3) NMOSD组 204 47(23.0) 12(5.9) 16(7.8) 18(8.8) 14(6.8) 10(4.9) χ2值 4.191 5.176 4.375 4.021 0.800 3.940 P值 0.041 0.023 0.036 0.045 0.371 0.047 注:劳累史为每天工作或玩耍10 h以上,每月24 d以上(包括工厂工人、送外卖人员、大学生、打麻将、玩手机者)。妇科手术指子宫或卵巢切除;产科手术指早期妊娠终止妊娠手术或剖宫产。经济收入水平为中高经济水平(≥3 000元/月),低经济水平(<3 000元/月)。 表 2 NMOSD患者危险因素的多因素分析
变量 B SE Wald χ2 P值 OR值 95% CI 女性 0.915 0.293 6.619 <0.001 2.473 1.714~3.486 低经济收入水平 0.648 0.397 5.145 0.036 1.502 1.020~2.121 劳累史 0.739 0.462 6.561 0.044 2.319 1.573~3.349 上呼吸道感染史 0.825 0.316 4.258 0.041 1.651 1.121~2.382 妇科手术/产科手术 0.874 0.498 5.357 0.023 1.712 1.060~3.375 创伤手术史 0.616 0.547 6.923 0.036 1.928 1.032~3.516 饮酒史 0.632 0.259 4.127 0.045 1.830 1.011~3.184 合并自身免疫疾病史 0.713 0.317 6.123 0.047 2.210 1.001~4.740 注:因变量为是否患NMOSD,否=0,是=1;自变量中性别,男性=0,女性=1;低经济水平,否=0,是=1;劳累史,否=0,是=1;上呼吸道感染史,否=0,是=1;妇科手术/产科手术,否=0,是=1;创伤手术史,否=0,是=1;饮酒史,否=0,是=1;合并自身免疫疾病史,否=0,是=1。 表 3 NMOSD患者的临床特点[例(%)]
组别 例数 首发症状 视神经受累 视神经损伤程度 脊髓损伤症状 脑干损伤症状 以视神经炎起病 以急性脊髓炎起病 视神经单侧受累 视神经双侧受累 视力下降 失明 双下肢瘫痪 感觉障碍 尿潴留 眼晕/眼球震颤/呕吐 饮水呛咳/吞咽困难 NMOSD初发组 117 60(51.3) 57(48.7) 56(47.9) 61(52.1) 90(76.9) 27(23.1) 15(12.8) 48(41.0) 5(4.3) 9(7.7) 2(1.7) NMOSD复发组 87 57(65.5) 30(34.5) 29(33.3) 58(66.7) 53(60.9) 34(39.1) 21(24.1) 50(57.5) 5(5.7) 15(17.2) 7(8.0) χ2值 4.134 4.334 6.098 4.398 5.406 0.232 4.383 4.751 P值 0.042 0.037 0.014 0.036 0.020 0.629 0.036 0.029 表 4 NMOSD患者的血清学、电生理和影像学特点[例(%)]
组别 例数 AQP4-IgG(+) 脑脊液 视觉诱发电位P100显著延长 影像学MRI 白细胞>50×106/L 蛋白>1 g/L 视神经肿胀增粗 脊髓受累病灶>6段 脑内脱髓鞘病灶 NMOSD初发组 117 72(61.5) 58(49.6) 27(23.1) 44(37.6) 42(35.9) 33(28.2) 8(6.8) NMOSD复发组 87 65(74.7) 55(63.2) 32(36.8) 46(52.9) 54(62.1) 50(57.5) 14(16.1) χ2值 3.926 4.237 4.559 4.717 13.718 16.423 4.442 P值 0.048 0.040 0.033 0.029 <0.001 <0.001 0.035 注:MRI脑内脱髓鞘病灶多位于皮质下、下丘脑、丘脑、三脑室周围、四脑室周围、大脑脚等部位,这些病灶不符合多发性硬化的影像学诊断学标准。 表 5 NMOSD患者的预后比较[例(%)]
组别 例数 生活自理 轮椅使用 全盲 死亡 NMOSD初发组 117 80(68.4) 14(12.0) 0(0.0) 0(0.0) NMOSD复发组 87 47(54.0) 22(25.3) 4(4.6) 3(3.4) χ2值 4.375 6.093 P值 0.036 0.014 0.032a 0.076a 注:生活自理ADL评分>60分。a为采用Fisher精确检验。 -
[1] CHEN H, LIU S M, ZHANG X X, et al. Clinical features of patients with multiple sclerosis and neuromyelitis optica spectrum disorders[J]. Chin Med J (Engl), 2016, 129(17): 2079-2084. doi: 10.4103/0366-6999.189046 [2] WINGERCHUK D M, BANWELL B, BENNETT J L, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. doi: 10.1212/WNL.0000000000001729 [3] HOUZEN H, KONDO K, NⅡNO M, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan[J]. Neurology, 2017, 89(19): 1995-2001. doi: 10.1212/WNL.0000000000004611 [4] JIAO Y, FRYER J P, LENNON V A, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica[J]. Neurology, 2013, 81(14): 1197-1204. doi: 10.1212/WNL.0b013e3182a6cb5c [5] VISWANATHAN S, WAH L M. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia[J]. Mult Scler, 2019, 25(11): 1452-1461. doi: 10.1177/1352458518792430 [6] SUN H, SUN X, LI J, et al. Gender differences among Chinese patients with neuromyelitis optica spectrum disorders[J]. Mult Scler Relat Disord, 2017, 17: 5-8. doi: 10.1016/j.msard.2017.06.008 [7] PALACE J, LIN D Y, ZENG D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders[J]. Brain, 2019, 142(5): 1310-1323. doi: 10.1093/brain/awz054 [8] KUNCHOK A, MALPAS C, NYTROVA P, et al. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder[J]. Mult Scler Relat Disord, 2020, 38: 101868. doi: 10.1016/j.msard.2019.101868 [9] AKAISHI T, TAKAHASHI T, FUJIHARA K, et al. Risk factors of attacks in neuromyelitis optica spectrum disorders[J]. J Neuroimmunol, 2020, 343: 577236. doi: 10.1016/j.jneuroim.2020.577236 [10] HOR J Y, ASGARI N, NAKASHIMA I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide[J]. Front Neurol, 2020, 11: 501. doi: 10.3389/fneur.2020.00501 [11] WINGERCHUK D M, HOGANCAMP W F, O'BRIEN P C, et al. The clinical course of neuromyelitis optica (Devic's syndrome)[J]. Neurology, 1999, 53(5): 1107. doi: 10.1212/WNL.53.5.1107 [12] MEALY M A, MOSSBURG S E, KIM S H, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions[J]. Mult Scler Relat Disord, 2019, 28: 64-68. doi: 10.1016/j.msard.2018.12.011 [13] RAFIEE F, TARJOMAN T, MOGHADASI A N, et al. Stressful life events, socioeconomic status, and the risk of neuromyelitis optica spectrum disorder: A population-based case-control study[J]. Mult Scler Relat Disord, 2020, 46: 102544. doi: 10.1016/j.msard.2020.102544 [14] ABDOLLAHPOUR I, NEDJAT S, SAHRAIAN M A, et al. Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study[J]. Mult Scler, 2017, 23(10): 1328-1335. doi: 10.1177/1352458516677867 [15] ETEMADI A, KHADEMI H, KAMANGAR F, et al. Hazards of cigarettes, smokeless tobacco and waterpipe in a Middle Eastern Population: a Cohort Study of 50000 individuals from Iran[J]. Tob Control, 2017, 26(6): 674-682. doi: 10.1136/tobaccocontrol-2016-053245 [16] KLAWITER E C, BOVE R, ELSONE L, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder[J]. Neurology, 2017, 89(22): 2238-2244. doi: 10.1212/WNL.0000000000004681 [17] TONG Y, LIU J, YANG T, et al. Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis[J]. Mult Scler Relat Disord, 2018, 25: 61-65. doi: 10.1016/j.msard.2018.07.006 [18] FRAGOSO Y D, SOUSA N A C, ALVES-LEON S V, et al. Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder[J]. Mult Scler Relat Disord, 2019, 27: 392-396. doi: 10.1016/j.msard.2018.11.031 [19] CHANG V T W, CHANG H M. Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder[J]. Neuropathol Appl Neurobiol, 2020, 46(3): 199-218. doi: 10.1111/nan.12574 [20] ZHANG W, CUI L, ZHANG Y, et al. Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population[J]. J Neurol, 2020, 267(4): 1197-1205. doi: 10.1007/s00415-019-09685-3 [21] JARIUS S, RUPRECHT K, WILDEMANN B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients[J]. J Neuroinflammation, 2012, 9(1): 14. doi: 10.1186/1742-2094-9-14 [22] 陈彧, 赵建民, 王夏红, 等. 视神经脊髓炎的视觉诱发电位和MRI对照研究[J]. 眼科新进展, 2008, 28(9): 698-699. https://www.cnki.com.cn/Article/CJFDTOTAL-XKJZ200809030.htm [23] MA X, KERMODE A G, HU X, et al. Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy[J]. Mult Scler Relat Disord, 2020, 46: 102522. doi: 10.1016/j.msard.2020.102522
计量
- 文章访问数: 347
- HTML全文浏览量: 232
- PDF下载量: 10
- 被引次数: 0